

## Chiesi Limited announces new senior level changes to leadership team

- *Tom Delahoyde will be retiring as General Manager of Chiesi Limited's UK and Ireland business as of December 2023*
- *Ralph Blom will join as new General Manager from January 2024*
- *David Garzón Lafuente will join as Rare Disease Business Unit Lead from January 2024*

**MANCHESTER, UK, 30 October 2023** – Chiesi, the international research-focused biopharmaceutical and healthcare group, today announced the appointment of Ralph Blom as the General Manager for Chiesi Limited (covering the UK and Ireland), beginning January 2024. Ralph will succeed Tom Delahoyde, who will retire at the end of December 2023. David Garzón Lafuente will also join as the Rare Disease Business Unit Lead in January 2024.

*"It's an honour to step into Tom's shoes, who has built such a strong foundation, and I am very excited to continue building upon this, prioritising patient care, driving our sustainability agenda and fostering a culture of excellence."* **said Ralph Blom, (incoming) Managing Director of Chiesi Limited (UK and Ireland).** *"We have a clear vision: be the point of reference for all stakeholders in the therapeutic areas we are active in, the company to turn to when you want to get things done. Together with our exceptional team, we will continue to deliver high-quality therapeutic solutions and uphold the values that define Chiesi."*

Ralph Blom has held senior positions at Chiesi Group for over 12 years, joining Chiesi Netherlands in 2011 as Special Care Sales & Marketing Manager, and later advancing to Respiratory Business Unit Manager. In 2016, he was appointed General Manager of Chiesi Netherlands. He is currently serving as the General Manager of Chiesi Benelux, a position he has held since 2022 and in which he has maintained substantial business growth.

Tom Delahoyde has played a significant role in establishing and leading the UK and Ireland company, beginning his Chiesi career when he transitioned from Trinity Pharmaceuticals when it was acquired by Chiesi Group in 1999. He was appointed as Managing Director and, under his leadership, the UK and Ireland arm of the Chiesi Group has achieved significant success, establishing Chiesi as a market leader in Respiratory and Neonatology in the UK.

*"I am immensely grateful for the journey I've had with Chiesi. Over the past 30 years, it has been a great honour to work alongside such a talented and dedicated team and to witness the positive impact we've made in improving patients' lives."* **said Tom Delahoyde, Managing Director of Chiesi Limited (UK and Ireland).** *"As I transition into retirement, I am confident that I leave the business in capable hands and wish everyone continued success."*

David Garzón Lafuente has over 19 years' experience in the pharma industry, previously holding senior positions within the Chiesi group including Business Unit Head of Rare Diseases for Chiesi Spain and Portugal. In 2022, he moved on to become General

## PRESS RELEASE

Manager at Amryt Pharma Iberia and Israel, and, following the Chiesi acquisition of Amryt earlier this year, will rejoin Chiesi as Rare Disease Business Unit Lead covering the UK and Ireland, effective from January 2024.

*"I am passionate about making an impact on patients' lives and excited to be back at Chiesi, now in the UK and Ireland where I will continue to focus on developing and implementing impactful initiatives with the team."* said **David Garzón Lafuente, Rare Disease Business Unit Lead of Chiesi Limited (UK and Ireland)**. *"My goal will be to ensure that we face challenges with determination and innovation with the ultimate aim of changing the lives of people with rare, debilitating conditions."*

###

**About Chiesi Group**

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit: [www.chiesi.uk.com](http://www.chiesi.uk.com).

**Media Contacts**

Yasmin Ghariani, Chiesi UK  
Head of External Communications  
Phone: (+44) 161 488 5555  
Email: [y.ghariani@chiesi.com](mailto:y.ghariani@chiesi.com)

Joanna Ly, OVID Health  
Senior Account Manager  
Phone: (+44) 7387753912  
Email: [Joanna.ly@ovidhealth.co.uk](mailto:Joanna.ly@ovidhealth.co.uk)